Zymeworks Common Stock Stock Investor Sentiment

ZYME Stock  USD 14.09  0.33  2.29%   
About 73% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
  

Zymeworks Common Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at benzinga.com         
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate ...
benzinga news
over three months ago at finance.yahoo.com         
NervGen Pharma Appoints Neil Klompas to Board of Directors
Yahoo News
over three months ago at simplywall.st         
Zymeworks shareholders are up 11 percent this past week, but still in the red over the last three ye...
Simply Wall St News at Macroaxis
over three months ago at benzinga.com         
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
benzinga news
over three months ago at globenewswire.com         
Zymeworks To Report Second Quarter 2024 Financial Results andHost Conference Call on August 1, 2024
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 21 T-ce...
Yahoo News
over three months ago at finance.yahoo.com         
Zymeworks investors are sitting on a loss of 75 percent if they invested three years ago
Yahoo News
over three months ago at talkmarkets.com         
Week In Review Osaka Enters 445 Million Deal For Two Hearing Loss Candidates From Frances Cilcare
news
over three months ago at simplywall.st         
Zymeworks Is In A Good Position To Deliver On Growth Plans
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Secon...
Yahoo News
over three months ago at investing.com         
Zymeworks set to receive 8 million milestone from BeiGene
Investing News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Kenneth Galbraith of 215000 shares of Zymeworks Common at 8.0 subject to Rule 16b-3
Macroaxis News
over six months ago at accesswire.com         
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi Korsinsky f...
news
over six months ago at accesswire.com         
Investors who lost money on Zymeworks Inc. should contact Levi Korsinsky about an ongoing investigat...
news
over six months ago at accesswire.com         
Zymeworks Inc. Shareholders May Have Been Affected by Fraud- Levi Korsinsky Investigates
news
Far too much social signal, news, headlines, and media speculation about Zymeworks Common that are available to investors today. That information is available publicly through Zymeworks media outlets and privately through word of mouth or via Zymeworks internal channels. However, regardless of the origin, that massive amount of Zymeworks data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zymeworks Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zymeworks Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zymeworks Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zymeworks Common alpha.

Zymeworks Common Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
GSK Q3 Earnings Surpass Estimates
10/30/2024
2
Zymeworks Inc. Reports Q3 Loss, Lags Revenue Estimates
10/31/2024
3
Zymeworks Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid Financial Challenges
11/01/2024
4
Leerink lifts Zymeworks stock target on pipeline progress
11/07/2024
5
Zymeworks Hits New 12-Month High Should You Buy
11/14/2024
6
Acquisition by Kenneth Galbraith of 215000 shares of Zymeworks Common at 8.0 subject to Rule 16b-3
11/20/2024
7
FDA Grants U.S. Approval of Ziihera for the
11/21/2024
8
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 SkyQuest Technology
11/27/2024

Complementary Tools for Zymeworks Stock analysis

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Directory
Find actively traded commodities issued by global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios